Document:

Offer Letter Agreement

 Exhibit 10.9 
 

 
 CONFIDENTIAL 
 June 12,
2007 
 Jeffrey L. Wong 
 Dear Jeffrey: 
 It has been a real pleasure discussing the opportunities ahead for Raining Data Corporation. We believe that you have the background and experience that
we need to help us grow in our new directions, and we are pleased to offer you a position with Raining Data Corporation (the “Company”) as its Vice President, Marketing. In that regards, the following are the details of this offer of
employment: 
 Title 
 Your title will be
Vice President of Marketing. In this position, you will report directly to me. 
 Base Compensation 
 Your initial annual base salary will be $175,000, paid in accordance with the Company’s normal payroll procedures. Your base salary shall be subject
to review at the end of each year of your employment, and any adjustment will be a function of performance, which I will evaluate and may be subject to approval of the Compensation Committee of the Board of Directors. 
 Incentive Bonus 
 Additionally, you will be entitled
to an annual incentive bonus of up to fifty percent (50%) of your base salary based on your meeting certain Management Business Objectives (MBOs) as are mutually agreed upon. You may also be eligible to receive a signing bonus of up to $10,000
in the event your current employer does not honor your quarterly compensation arrangement. 
 Stock Options 
 At a Compensation Committee Meeting (or sub-committee meeting) that will be held on your actual
start date, you will granted a stock option, which shall be, to the extent possible under the rule of Section 422(d) of the Internal Revenue Code of 1986, as amended (the “Code”), an “incentive stock option” (as defined in
Section 422 of the Code) to purchase 250,000 shares of the Company’s Common Stock, at an exercise price equal to the then NASDAQ market price as of the close of the markets on the day of that meeting Twenty-five percent (25%) of the
shares subject to the above option shall vest one year after your start date and 1/48th of the shares subject to the option shall vest monthly
thereafter, so that the option shall be fully vested and exercisable four years from your start date, subject to your continued service to the Company on the relevant vesting dates. In all other respects the option shall be subject to the terms,
definitions and provisions of the Company’s Stock Plan and the stock option agreement by and between you and the Company, both of which documents are incorporated herein by reference. 
 Change of Control, Additional Accelerated Vesting and Related Items 
 In addition to the vesting schedule as set forth above, in the event you are terminated as a result of an Involuntary Termination other than for Cause or Disability within 12 months after a Change of Control, one
hundred percent (100%) of the shares subject to the above option shall be vested upon the date of such 

 
termination, provided that you sign a general release in a commercially customary form prescribed by the Company, which releases and discharges all known and
unknown claims that you may have against the Company or persons and entities affiliated with the Company, and a covenant not to sue or prosecute any legal action or proceedings based upon such claims. For the purposes of this paragraph, the
following terms shall have the following meanings: 
  

	 	A)	“Cause” shall mean 

  

	 	i)	Gross and willful failure to perform services; 

  

	 	ii)	Conviction of, or a plea of “guilty” or “no contest” to, a felony under the laws of the United States or any state thereof, if such felony either is work-related
or materially impairs your ability to perform services for the Company; 

  

	 	iii)	A material breach of fiduciary duty, including fraud, embezzlement, dishonesty or any intentional action that materially injures the Company as determined in good faith by the
Company’s Board of Directors; 

  

	 	iv)	Death; 

  

	 	v)	A material breach of the Confidential Information Agreement. 

 In all of the foregoing cases, the Company shall provide written notice to you indicating in reasonable detail the event or circumstances that constitute Cause under this Agreement and the Company will provide you with forty-five days to
cure such breach or failure prior to termination for Cause. During such 45-day cure period, the Company may place you on unpaid leave. 
  

	 	B)	“Change in Control” shall mean (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) who becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power
represented by the Company’s then outstanding voting securities, provided, however, that Change in Control shall not include any change resulting from any capital financings of the Company; or (ii) the consummation of the sale or
disposition by the Company of all or substantially all of the Company’s assets; or (iii) the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in
the voting securities of the company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent
(50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. 

  

	 	C)	“Disability” shall mean that you physically or mentally are unable regularly to perform your duties hereunder for a period in excess of sixty (60) consecutive days or
more than ninety (90) days in any consecutive twelve (12) month period. The Company shall make a good faith determination of whether you are physically or mentally unable to regularly perform your duties subject to its review and
consideration of any physical and/or mental health information provided to it by you. 

  

	 	D)	“Involuntary Termination” shall mean (i) without your express written consent, the substantial reduction your duties or responsibilities relative to your duties or
responsibilities in effect immediately prior to such reduction; provided, however, that a reduction in duties or responsibilities solely by virtue of the Company being acquired and made part of a larger entity (as, for example, when the Vice
President of Company remains as such following a Change of Control and is not made the Vice President of the acquiring corporation) shall not constitute an “Involuntary Termination”; (ii) without your express written consent, a
material reduction by the Company in your base compensation as in effect immediately prior to such reduction; (iii) a material reduction by the Company in the kind or level of employee benefits package is significantly reduced; (iv) your
relocation to a facility or a location more than 50 miles from your then present location, without your express written consent; (v) any purported termination of you by the Company which is not effected for death or Disability or for Cause; or
(vii) the failure of the Company to obtain the assumption of this agreement by any successors. 

 Noncompetition and Nonsolicitation 
 Additionally, for a period of one (1) year following the termination of your employment for any reason, you agree that you will not, directly or indirectly, (A) divert or attempt to divert from the Company
(or any Affiliated Company) any business of any kind in which it is engaged, including, without limitation, the solicitation of or interference with any of its suppliers or customers; or (B) solicit, hire, recruit, or employ any person or
entity who is employed by or has a contractual relationship with the Company, or encourage any person or entity who is employed by or has a contractual relationship with the Company to terminate their employment or contractual relationship with the
Company. 
 Benefit Plans 
 You shall be
entitled to participate, to the extent permitted by law, in the medical insurance plans and other benefits offered by the Company. You should note that the Company reserves the right to cancel or change the benefit plans and programs it offers to
its employees at any time. 
 Vacation and Sick Leave 
 You shall be eligible to receive two weeks of paid time-off per year, which, if unused, shall accrue in accordance with the Company’s standard benefit policies. You shall also be able to take up to five days of
paid sick leave per calendar year, which does not accrue and cannot be carried over from one calendar year to the next. 
 Start Date 
 We hope that you will be able to start with the Company as soon as possible. However, in any case your start date will be on or prior to August 1,
2007. 
 The Company is excited about your joining and looks forward to a beneficial and fruitful relationship. Nevertheless, you should be
aware that your employment with the Company is for no specific period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to conclude its employment
relationship with you at any time, with or without cause and with at least one-month notice. We request that, in the event of resignation, you give the Company at least one month’s notice. You understand and agree that neither your job
performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of your employment with the Company. 
 Miscellaneous 
 For purpose of federal immigration
law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to the Company within three (3) business days of your date of
hire, or our employment relationship with you may be terminated. This Agreement and all benefits due you hereunder shall inure to the benefit of, and be enforceable by, your personal or legal representatives, executors, administrators, successors,
heirs, distributees, devisees and legatees. 
 We also ask that, if you have not already done so, you disclose to the Company any and all
agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any such agreements will not prevent you from
performing the duties of your position and you represent that such is the case. 
 You agree that you will not enter into any agreements with
another entity that requires you to be an employee or consultant, in name or duties, during your employment with the Company. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment,

 
occupation, consulting or other business activity directly related to the business in which the Company is now involved or become involved during the term of
your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly, you agree not to bring any third party confidential information to the Company, including that of your former employer, and
that in performing your duties for the Company you will not in any way utilize any such information. 
 As a Company employee, you will be
expected to abide by Company rules and standards. You will be specifically required to sign an acknowledgment that you have read and that you understand the Company’s rules of conduct with are included in the Company Handbook. As a condition of
your employment, you are also required to sign and comply with an Employment, Confidential Information, Invention Assignment and Arbitration Agreement which requires, among other provisions, the assignment of patent rights to any invention made
during your employment at the Company, and non-disclosure of Company proprietary information. In the event of any dispute or claim relating to or arising out of your employment relationship, you and the Company agree that (i) any and all
disputes between you and the Company shall be fully and finally resolved by binding arbitration, (ii) you are waiving any and all rights to a jury trial but all court remedies will be available in arbitration, (iii) all disputes shall be
resolved by a neutral arbitrator who shall issue a written opinion, (iv) the arbitration shall provide for adequate discovery, and (v) the Company shall pay all arbitration fees, excluding attorneys fees and legal costs. Please note that
we must receive your signed Agreement by your first day of employment. 
 This letter shall be governed by the internal substantive laws, but
not the choice of law rules, of the State of California. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or void, this letter shall continue in full force and effect
without such provision. In the event that there is any conflict between this offer letter and your Stock Option Plan or Stock Option Agreement, this offer letter will govern. 
 To indicate your acceptance of the Company’s offer, please sign and date this letter in the space provided below. A duplicate original is enclosed
for your records. This letter, along with any agreements relating to proprietary rights between you and the Company, sets forth the terms of your employment with the Company and supersedes any prior representations or agreements including, but not
limited to, any representation made during your recruitment, interviews or pre employment negotiations, whether written or oral. This letter, including, but not limited to, its at-will employment provision, may not be modified or amended except by a
written agreement signed by the Company’s Chief Executive Officer and you. This offer of employment will terminate if it is not accepted, signed and returned by August 1, 2007, or unless otherwise withdrawn by the Company prior to your
acceptance. 
 Jeffrey, we all look forward to working with you at Raining Data, and believe that your contributions will be significant in
moving the Company into its new market opportunities. 
 Best regards, 
 Carlton H. Baab 
 President & CEO 
 Raining
Data Corporation 
 AGREED AND ACCEPTED: 
  

							
	 /s/ Jeffrey L. Wong
	  		  	 June 12, 2007
	  	
	Jeffrey L. Wong	  		  	DateRevised Letter of Payment Authorization

 Exhibit 10.1 
 

 
 Revised Letter of Payment Authorization 
 June 17, 2008 
 Dr. Jay Lichter 
 Akesis Pharmaceuticals, Inc. 
 888 Prospect Street 
 Suite 320 
 La Jolla, CA 92037 
 E: jlichter@avalon-ventures.com 
 Dear Dr. Lichter, 
 We thank you for your interest in Charles River Laboratories and hope the attached proposal meets with your approval. For your convenience, we have provided the following summary of the titles and prices of the studies and/or study
components under discussion. If you would like us to proceed with animal orders resource allocation, please initial the studies and components you wish to authorize at this time and sign and date the authorization line below. These prices are valid
for 60 days, but may be modified by mutual agreement if changes to the scope of work are made. 
  

					
	 Authorization
 Initial’s
	  	 Study Number and Title
	  	 Price
 (US Dollars)

		  	 LTC00013
 13-Week Toxicity Study in Sprague-Dawley Rats
with 4 Weeks Recovery 
 (Reference scope of work dated: 06/17/2008 version 1)
	  	
		  	Core Study Price:	  	 $446,500
 (price includes 5% discount)

			
		  	 210935
 Dose Solution Analysis of Vanadium (AKP-020) by
GFAAS in support of LTC00013
	  	 $7,000
 1
st occasion
 $3,600 subsequent occasions

			
		  	 665350
 Biomechanical Testing on Rat Femur in support of
LTC00013
	  	$36,000
			
		  	 141426
 Analysis of rat whole blood samples from study
LTC00013 for the determination of Vanadium by GFAAS
	  	$165.00/samples (Minimum batch size of 50 samples)
			
		  	 141427
 Analysis of rat tissue samples from study
LTC00013 for the determination of Vanadium by GFAAS
	  	$250.00/samples (Minimum batch size of 50 samples)
			
		  	 480075
 TK Interpretation, linked to 141426 in support of
LTC00013
	  	$6,700

  

			
	 Charles River Laboratories
	  	Page 1 of 11

					
	 Authorization
 Initial’s
	  	 Study Number and Title
	  	 Price
 (US Dollars)

		  	 LTC00014
 13-Week Toxicity Study in Beagle Dogs with 4
Weeks Recovery
 (Reference scope of work dated: 06/17/2008 version 1)
	  	
		  	Core Study Price:	  	 $613,605
 (price includes 5% discount)

			
		  	 210936
 Dose Solution Analysis of Vanadium (AKP-020) by
GFAAS in support of LTC00014
	  	 $7,000
 1
st occasion
 $3,600 subsequent occasions

			
		  	 141428
 Analysis of dog whole blood Samples from study
LTC00014 for the determination of Vanadium by GFAAS
	  	$165.00/samples (Minimum batch size of 50 samples)
			
		  	 141429
 Analysis of dog tissue samples from study
LTC00014 for the determination of Vanadium by GFAAS
	  	$250.00/samples (Minimum batch size of 50 samples)
			
		  	 480076
 TK Interpretation, liked to
141428
	  	$25,000

 In order to minimize the impact of study delays and cancellations for all sponsors, Charles River allocates
resources at the time a signed Letter of Payment Authorization is received. Please note that scheduling is not considered confirmed until a signed copy of this document is received. By providing authorization via signature below, you will
allow us to confirm a schedule for each authorized study. Your signature further constitutes acceptance of the price and payment schedule. 
 Price and
Payment Schedule for Study LTC00013 
 The payment schedule and price of this study are as follows: 
  

	 	•	 	 30%       Due upon Authorization* 

  

	 	•	 	 30%       Due upon Study Initiation 

  

	 	•	 	 30%       Due upon Completion of In-Life 

  

	 	•	 	 10%       Due upon Submission of Draft Report 

  

	*	Invoice(s) will be sent no more than 60 days prior to scheduled study start. 

 Price and Payment Schedule for Study LTC00014 
 The payment schedule and price of this study are as follows: 
  

	 	•	 	 30%       Due upon Authorization* 

  

	 	•	 	 30%       Due upon Study Initiation 

  

	 	•	 	 30%       Due upon Completion of In-Life 

  

	 	•	 	 10%       Due upon Submission of Draft Report 

  

	*	Invoice(s) will be sent no more than 60 days prior to scheduled study start. 

  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 2 of 11

 In the event Charles River does not receive comments pertaining to the draft report within 60 days after submission to
the Sponsor, the final invoice will be due and payable. 
 We understand that occasionally you may request to delay or to cancel a study due to unforeseen
circumstances. Charles River will make every reasonable effort to accommodate requested schedule changes. However, as significant costs are incurred related to study initiation, cancellation/delay fees will apply in proportion to the number of
days’ notice given (please see attached Cancellation and Delay Policy). Cancellation/delay fees may be assessed separately for each postponement prior to the study being cancelled or initiated. The Cancellation and Delay Policy becomes
effective upon execution of this Letter of Authorization. 
 Charles River shall perform these services in accordance with the Service Agreement (the
“Agreement”) executed between Charles River Laboratories and Akesis Pharmaceuticals, Inc. Once fully executed, this Letter of Payment Authorization shall be incorporated into and made part of the Agreement. 
 REPEAT OF SAMPLE ANALYSIS. If applicable, the parties agree that as of commencement of work, in some instances, repeat of sample analysis will be required. If
this arises, Charles River must notify the Sponsor as soon as possible and determine, between the parties, if these repeats are required by Sponsor. Consequently, the price per sample analysis/occasion will apply to any additional repeats requested
by the Sponsor, as well as any samples above the analytical range, which require dilution. However, in the event that additional sample analysis/occasions are required, Charles River shall submit a written estimate to the Sponsor for the
Sponsor’s written approval, and the Sponsor shall respond to Charles River within five (5) business days, or within the specified time period sanctioned by the Sponsor for receipt of such estimates. Once authorization is received, Charles
River will endeavor, when possible, to proceed with current batches of sample analysis. Both parties acknowledge that Charles River will be reimbursed for any amount which relates to the repeats if the difference between the original result of the
sample analysis and the repeat result of the sample analysis, is within a 30% range. 
 SHIPMENT OF TEST ARTICLES. Sponsor and Charles River agree
that all costs associated with shipping test article to Charles River shall be the responsibility of the Sponsor. Charles River shall not be responsible for any direct or indirect damages sustained by the Sponsor resulting from any loss, destruction
or damage to the test article(s). 
 In the event of a conflict between the terms set forth in this letter and the Master Service Agreement, the terms of the
Master Service Agreement shall control, unless specifically agreed upon to the contrary in this letter. 
 Please sign and return this document via facsimile
or email (contact information below). Should you have any questions or require any additional information, please do not hesitate to call me. We look forward to being of service. 
  

			
	Best Regards,	 	
	

	 	/s/ Jay B. Lichter Ph.D.
	 	Authorized Sponsor Representative
	 	  
 President and
CEO

	 	Print (Name and Title)
		
	 Christina Fox
	 	  
 6/18/08

	 Account Manager
 Charles River Laboratories, Inc.
 Preclinical Services
 Phone:   508.925.6270
 Fax:
       508.925.6701
 E-Mail: Christina.Fox@crl.com
	 	Date
	 	
	 	

 If a PO is required, please submit PO with Letter of Payment Authorization or fax to Corporate Finance at
978.657.4242. 
  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 3 of 11

									
	Title:	  	13-Week Toxicity Study in Sprague-Dawley Rats with 4 Weeks Recovery
		
	Study Number:	  	LTC00013 Version 1
		
	Charles River Facility:	  	Charles River Laboratories Preclinical Services Massachusetts
		
	Compliance:	  	GLP
		
	Species/Strain:	  	Rat, Sprague-Dawley
		
	Dose Formulation Preparation (assumes basic dose preparation):	  	Suspension
		
	Dose Formulation Analysis:	  	Dose Solution Analysis of Vanadium (AKP-020) by GFASS
		
	Dosing Regimen:	  	1x/day, for 13 weeks
		
	Route of Administration	  	Oral Gavage
					
	Test System:	  		 		  		  	
				
	Main Study Animals:	  	10/sex/group	  		  	
		
	Recovery Animals:	  	5/sex/group
					
	Recovery:	  	Included	 		  		  	
		
	Test Article:	  	AKP-020 (monotherapy)
		
	Control Article:	  	1% carboxymethylcellulose
				
	Study Design:	  	 Group
	 	Dose
(mpkpd)	  	 Number of Animals

	  	 	  	 M
	  	 F

		  	1 (Control)	 	0	  	15 MS + 3 TK	  	15 MS + 3 TK
		  	2	 	2.5	  	15 MS + 9 TK	  	15 MS + 39 TK
		  	3	 	5	  	15 MS + 9 TK	  	15 MS + 9 TK
		  	4	 	10	  	15 MS + 9 TK	  	15 MS + 9 TK
		  	MS = main study; TK = toxiccokinetic
 10 spars/sex

	In-Life:	  		 		  		  	
	Mortality:	  	MS and TK animals, 2x daily (AM, PM)
		
	Clinical Observation:	  	MS animals, 1x daily
		
	Body Weight:	  	MS and TK animals, pretest, weekly
 MS animals, prior to necropsy
(fasted)

		
	Food Consumption:	  	MS animals, weekly
		
	Ophthalmology:	  	MS and TK animals, pretest
 MS animals, prior to necropsy
 Evaluations by a board-certified veterinary ophthalmologist

		
	Toxicokinetics:	  	For 3/sex/group, Days 1 and 91 at the following timepoints: 0.5, 1, 2, 3, 6, 12 and 24 hours; Samples collected and analyzed for determination of Vanadium by GFAAS: Whole
Blood

  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 4 of 11

			
	Bioanalytical Sample Analysis:	  	Included (whole blood and tissue samples collected and analyzed for determination of Vanadium by GFAAS)
		
	Toxicokinetic Data Evaluation (blood):	  	12 runs
		
	Clinical Pathology	  	
		
	Serum Chemistry:	  	MS animals, Pre study (limited panel), 1 month, 3 month and recovery prior to necropsy (fasted)
		
	Hematology:	  	MS animals, pre study, 1 month, 3 month and recovery (prior to necropsy)
		
	Coagulation:	  	MS animals, Prior to MS and recovery necropsy
		
	Urinalysis:	  	All animals, pre study, 1 month, 3 months and recovery Urine collected via metabolism cage
		
		  	Urine parameters: NAG
		
		  	Calculate and report electrolyte data (Ca, P, K, Na and Cl) using ratios and fractional excretion as appropriate.
		
	Anatomical Pathology	  	
		
	Gross Necropsy:	  	MS animals, end of dose necropsy, and recovery
		
	Organ Weights:	  	Organ Weights: MS animals, end of dose necropsy, and recovery
		
	Histopathology:	  	All animals, histopathologic evaluation (Kidney, Liver, Lung, Heart, Pancreas, adipose) control and high dose animals, read down as necessary with additional pricing. Bone marrow smears
collected, slides made, evaluated if necessary
		
	Special Assessments:	  	Kidney Cortex collected and possible evaluated for EM (40 samples)
		
		  	Kidney & Pancreas collected and possibly evaluated for IHC (80 samples)
		
		  	Femur collected and analyzed by DXA, pQCT and 3-point bending (40 samples)
		
		  	Tabulated results and report
		
		  	GLP
		
		  	Samples collected and analyzed for determination of Vanadium by GFAAS: Bone, Kidney, Liver, Pancreas, Heart, Lung, Muscle, and Fat
		
	Data Analysis:	  	Qualitative and quantitative as appropriate
		
	Report Requirements:	  	Draft and Final
		
		  	Standard reporting requirements include one draft and one final report in the Charles River format. Issuance of additional drafts, reports, amended reports or a custom format request may
result in an additional fee.

  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 5 of 11

			
	Archiving:	  	One Year
		
		  	After dispatch of the draft report, all raw data, samples/specimens (except for those sent to Sponsor or Sponsor designated laboratory and resultant data which are the responsibility of
Sponsor) and documents generated at Charles River during this study, together with the original or copy of the protocol (including amendments) and the draft report (if available), will be retained in the secure storage area of Charles River for one
(1) year. After this one (1) year period, Sponsor will be contacted prior to the end of the year to authorize continued storage or return to Sponsor, at additional cost (extended storage may be at another Charles River location). At finalization,
the final report and any stored materials will be transferred to the scientific archives of Charles River. Subsequently, storage details will be documented in the raw data.
		
		  	Any additional storage, archiving or retention will require an Extended Archiving Agreement

  

	*	For the recovery phase, Charles River Laboratories reserves the right to house the animals in a smaller room which may or may not house recovery animals from other studies.
Should the Sponsor not want the animals to be moved, an additional charge may be applied. 

 Modifications or alterations can be made to
the study design to suit specific test article and client needs. Modifications may alter pricing and scheduling. 
  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 6 of 11

									
	Title:	  	13-Week Toxicity Study in Beagle Dogs with 4 Weeks Recovery
		
	Study Number:	  	LTC00014 Version 1
		
	Charles River Facility:	  	Charles River Laboratories Preclinical Services Massachusetts
			
	Compliance:	  	GLP	  	
			
	Species/Strain:	  	Dogs, Beagle	  	
		
	Dose Formulation Preparation (assumes basic dose preparation):	  	PO= Per OS, Once daily capsule formulation
		
	Dose Formulation Analysis:	  	Dose Solution Analysis of Vanadium (AKP-020) by GFASS
		
	Dosing Regimen:	  	1x/day, for 13 weeks
		
	Route of Administration	  	Capsule
		
	Test System:	  	
		
	Main Study Animals:	  	3/sex/group
		
	Recovery Animals:	  	3/sex/group
		
	Recovery:	  	4 Weeks
		
	Test Article:	  	AKP-020
		
	Control Article:	  	TBD
				
	Study Design:	  	Group	 	Dosage
(mpkpd)	  	 Number of Animals (Including Recovery)

	  	 	  	 M
	  	 F

		  	1 (Control)	 	0	  	6	  	6
		  	2	 	0.3	  	6	  	6
		  	3	 	1	  	6	  	6
		  	4	 	3	  	6	  	6
		  	3 spares/sex
					
	In-Life:	  		 		  		  	
		
	Mortality:	  	All animals, 2x daily (AM, PM)
		
	Clinical Observation:	  	All animals, 1x daily cageside obs including 1 week prior to dosing, detailed obs weekly
		
	Body Weight:	  	All animals, 2x pretest including, weekly, prior to necropsy (fasted)
		
	Food Consumption:	  	All animals, daily including 1 week prior to dosing
		
	Veterinary Exams:	  	Pretest and prior to necropsy
		
	Electrocardiography:	  	All animals, pretest, prior to necropsy, no blood pressure Qualitative data evaluation by a Board-certified veterinary cardiologist
		
	Opthamology:	  	All animals, pretest, prior to necropsy Exams conducted by a Board-certified ophthalmologist

  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 7 of 11

			
	Title:	  	13-Week Toxicity Study in Beagle Dogs with 4 Weeks Recovery
		
	Study Number:	  	LTC00014 Version 1
		
	Toxicokinetic Collection/Frequency:	  	All animals, Days 1, 28 and 91 at the following timepoints: Pre-dose(Days 28 and 91 only), 0.5, 1, 2, 3, 6, 12 and 24 hours; Recovery animals Day 112 prior to necropsy. Whole blood and tissue
samples collected and analyzed for determination of Vanadium by GFAAS.
		
	Toxicokinetic Sample Analysis:	  	Included (Samples collected and analyzed for determination of Vanadium by GFAAS)
		
	Toxicokinetic Data Evaluation (bloods):	  	108 Runs
		
	Clinical Pathology	  	
		
	Serum Chemistry:	  	All animals, pretest, and Week 4, Week 13 (fasted), Recovery Week 17
		
	Hematology:	  	
		
	Coagulation:	  	
		
	Urinalysis:	  	All animals, pretest, 1 month, 3 months and recovery Urine collected by pan collection or cystocentesis (prior to necropsy)
		
	Special Assessments:	  	Urine parameters: NAG, GGT, Beta-2-Microglobulin, Protein, Creatinine, Ca++, and Phosphate
		
		  	Calculate and report data using ratios and fractional excretion as appropriate. All animals, comprehensive
		
	Anatomical Pathology	  	
		
	Gross Necropsy:	  	All animals, comprehensive
		
	Organ Weights:	  	All animals, standard list
		
	Histopathology:	  	All animals, full gross histopathologic evaluation (Kidney, Liver, Heart, Pancreas, adipose) control and high dose animals, read down as necessary with additional pricing. Bone marrow smears
collected, slides made, evaluated if necessary
		
	Special Assessments:	  	Kidney Cortex collected and possibly evaluated for EM (40 samples)
		
		  	Kidney & Pancreas collected and possibly evaluated for IHC (80 samples)
		
		  	Samples collected and analyzed for determination of Vanadium by GFAAS: Bone, Kidney, Liver, Pancreas, Heart, Lung, Muscle, and tissues TBD
		
	Data Analysis:	  	Qualitative and quantitative as appropriate Draft and Final
		
	Report Requirements:	  	Draft and Final
		
		  	Standard reporting requirements include one draft and one final report in the Charles River format. Issuance of additional drafts, reports, amended reports or a custom format request may result
in an additional fee.

  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 8 of 11

			
	Title:	  	13-Week Toxicity Study in Beagle Dogs with 4 Weeks Recovery
		
	Study Number:	  	LTC00014 Version 1
		
	Archiving:	  	One Year
		
		  	After dispatch of the draft report, all raw data, samples/specimens (except for those sent to Sponsor or Sponsor designated laboratory and resultant data which are the responsibility of
Sponsor) and documents generated at Charles River during this study, together with the original or copy of the protocol (including amendments) and the draft report (if available), will be retained in the secure storage area of Charles River for one
(1) year. After this one (1) year period, Sponsor will be contacted prior to the end of the year to authorize continued storage or return to Sponsor, at additional cost (extended storage may be at another Charles River location). At finalization,
the final report and any stored materials will be transferred to the scientific archives of Charles River. Subsequently, storage details will be documented in the raw data.
		
		  	Any additional storage, archiving or retention will require an Extended Archiving Agreement

  

	*	For the recovery phase, Charles River Laboratories reserves the right to house the animals in a smaller room which may or may not house recovery animals from other studies.
Should the Sponsor not want the animals to be moved, an additional charge may be applied. 

 Modifications or alterations can be made to
the study design to suit specific test article and client needs. Modifications may alter pricing and scheduling. 
  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 9 of 11

 POSTPONEMENT/CANCELLATION POLICY 
 Upon receipt of the signed quote letter or correspondence from the Sponsor confirming formal authorization, Charles River Laboratories Preclinical Services, hereinafter referred to as (“Charles River”) will
order or reserve animals and allocate other resources for the specified study. 
 If the study is initiated on the scheduled start date, the most current
quoted price is valid (unless advised otherwise by any revised quote letter) and no postponement or cancellation charges are applicable. 
 There will be no
charges if the study is rescheduled or cancelled as long as notice is provided to Charles River in advance of the defined period of time prior to the animal arrival date, as stipulated below: 
  

	 	•	 	 Rodents: 28 days 

  

	 	•	 	 Dogs: 59 days 

  

	 	•	 	 Non-Human Primates: 59 days 

 Should any applicable
fees be charged from the animal supplier before the above-mentioned timelines, these would be the responsibility of the Sponsor. 
 Postponement
Terms: 
 Prior To and Following Animal arrival: 
 Notice of postponement of the study by the Sponsor for any study with a duration of 28 days or more, through no fault of Charles River, prior to or following Animal arrival, shall be charged to the Sponsor at a rate based on the calculation
of the total value of the study divided by the total weeks of the study duration, including weeks of acclimation period. Should the study be less than 28 days, Sponsor shall be charged at a rate of $10,500 per week of delay (“Housing
Fees”). If the delay exceeds more than four weeks, it would automatically be subject to the cancellation terms below. 
 In any cases, Housing Fees do
not include any technical work such as surgical preparation or other scientific procedures required in order to maintain the integrity of the study, which will be at additional cost. 
 Cancellation Terms: 
 Cancellation of the study by the Sponsor, through no fault of Charles River, which falls
within the defined period of time above, will be assessed as follows: 
 Cancellation Charges 
  

						
	 Days of Notice Given Prior to
Animal Arrival (Rodents)
	 	Days of Notice Given Prior to
Animal Arrival (Dogs & Non-
Human Primates)
	 	Entire cost of animal fees (if
applicable) + Cancellation
Charge (% of Study Price)	 
	1 – 7	 	1 – 7	 	50	%
	8 – 14	 	8 – 14	 	40	%
	15 – 28	 	15 – 28	 	30	%
	N/A	 	29 – 59	 	20	%

  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 10 of 11

 If sponsor cancels study after animal arrival and before study start the following charges will apply: 
 50% of total study price plus animal costs plus husbandry ($10,500 room/week) until relocation of animals or disposal. 
 If the Sponsor requests postponement of a study start, we will make every effort to accommodate the requested change; however, due to resource constraints, Charles River
may not be able to reschedule the study precisely as requested by the Sponsor. If the new schedule is not acceptable, the Sponsor may elect to cancel the study, in which case the applicable cancellation charge would apply. 
 In the event of postponement or cancellation of the study by the Sponsor, additional compensation may be requested
for items procured specifically for the study (e.g., animal purchases1, dedicated equipment, perishable or non-reusable supplies) and any
non-recoverable expenses incurred by Charles River (e.g., equipment lease payments, subcontractor charges or consultant fees to which Charles is irrevocably committed). 
 In the event the Sponsor terminates an ongoing study (i.e. early termination following dosing initiation), the Sponsor will be responsible for all incurred costs, committed costs and lost opportunity charges.

 Exceptions to the above terms may be made on a case-by-case basis at Charles River sole discretion, if the study cancellation or postponement has little
or no financial impact on Charles River (e.g. if notice that the study is subsequently cancelled or postponed falls within the defined period of time above pre-study period but no resources have been expended or costs incurred in the preparation for
the study, and the animals can be readily used in another study [or exchanged, in the case of postponement]). 
 In the event of a conflict between the terms
set forth in this letter and the Master Service Agreement, the terms of the Master Service Agreement shall control, unless specifically agreed upon to the contrary in this letter. 
  

	 1
	 In order to secure animals, Charles River is required to purchase the animals
upon study authorization. Therefore, should there be a cancellation thereafter by the Sponsor, the Sponsor will incur the full cost of animals ordered. 

  

			
	 Date Created: June 17, 2008
 Sponsor: Akesis Pharmaceuticals, Inc.
	  	Page 11 of 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}]]